ClinicalTrials.gg
RecruitingNCT07322094Updated Jul 13, 2026

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

A Phase 1/2 interventional study of TORL-1-23 and paclitaxel and TORL-1-23 and carboplatin in FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers and Primary Peritoneal Cancer, sponsored by TORL Biotherapeutics, LLC. Recruiting at 7 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by TORL Biotherapeutics, LLC · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing paclitaxel in Fallopian Tube Neoplasms — 7 open to participants now, 13 under way, 4 of them phase 3. Paclitaxel · Fallopian Tube Neoplasms.

Planned enrollment
31st of 69
60 · median 46
Started
2025
the only one that year
Phase 1/2
Only one
of the 73
Primary completion
2027-12
later than 11 of 12 live
Registered
74th of 73
by date

Among the 73 studies testing paclitaxel in Fallopian Tube Neoplasms, this one is the 31st largest by planned enrollment of the 69 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1/2, reaches primary completion later than 11 of the 12 other live ones, and was the 74th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

7 of the 73 studies testing paclitaxel in Fallopian Tube Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing paclitaxel in Fallopian Tube Neoplasms, or all of them as a file.
02

Study summary

A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer

03

Conditions studied

  • FIGO Stage III and IV Ovarian Cancer
  • Fallopian Tube Cancers
  • Primary Peritoneal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status 0 to 1
  • or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer
  • FIGO Stage III or IV
  • Positive for claudin 6 (CLDN6) expression
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Clear cell, mucinous, sarcomatous, mixed histology, low-grade/borderline, or non-epithelial ovarian cancers
  • Prior systemic treatment for the disease under study
  • Prior surgery
  • Prior radiation therapy to the abdomen or pelvis
  • Current recipient or receipt within 5-half-lives of C1D1 of any of the following: chemotherapy, biologic/targeted therapy, herbal medications or supplements, immunomodulator therapy for any disease indication.
  • History of noninfectious pneumonitis/interstitial lung disease (ILD) within 6 months of first dose of study drug.
  • Active, progressive, or symptomatic
  • Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment Arm A: TORL-1-23 and paclitaxel

    Administered once every three weeks

    Combination Product: TORL-1-23 and paclitaxel

  • Experimental
    Treatment Arm B: TORL-1-23 and carboplatin

    Administered once every three weeks

    Combination Product: TORL-1-23 and carboplatin

  • Experimental
    Treatment Arm C: TORL-1-23, paclitaxel, and carboplatin

    Administered once every three weeks

    Combination Product: TORL-1-23, paclitaxel, and carboplatin

Interventions

  • Combination productTORL-1-23 and paclitaxel

    Drug pages: Ixotatug vedotin · Paclitaxel

    TORL-1-23 and paclitaxel

  • Combination productTORL-1-23 and carboplatin

    Drug pages: Ixotatug vedotin · Carboplatin

    TORL-1-23 and carboplatin

  • Combination productTORL-1-23, paclitaxel, and carboplatin

    TORL-1-23, paclitaxel, and carboplatin

06

What researchers measure

Primary outcomes

  1. Characterize the safety and feasibility of TORL-1-23 in combination with chemotherapy by analyzing the incidence of treatment emergent adverse events and serious adverse events.

    Incidence of Grade greater than or equal to 3 (using CTCAE V5.0) treatment-emergent adverse event (TEAE) and related serious adverse event (SAE)

    Time frame: Treatment during Cycle 1 to Cycle 4 (Each cycle is 21 days)

  2. To assess the efficacy of neoadjuvant TORL-1-23 in combination with chemotherapy

    Determination of percentage CRS3 score for each treatment arm

    Time frame: postoperative after Cycle 4 (Each cycle is 21 days)

Secondary outcomes

  1. To assess the tolerability of TORL-1-23 in combination with chemotherapy

    Safety assessed by incidence of intolerable Grade 2 and Grade greater than or equal to 3 TEAE and related SAE.

    Time frame: Treatment up to Cycle 8 (each cycle is 21 days)

  2. To characterize duration of benefit for TORL-1-23 plus chemotherapy

    Relapse free survival for participants

    Time frame: Measured up to 15 months after surgery

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 37 phase 1/2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 110. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Jan 7, 2026
StartActual
Dec 10, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jan 2028
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07322094
Lead sponsor
TORL Biotherapeutics, LLC
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Dec 10, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Caroline Labib, PharmD
Contact
caroline.labib@torlbio.com
310-348-9636

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixotatug vedotin · Paclitaxel · Carboplatin

Start the discussion